cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Belite Bio Inc Adr
2 watching
Current Price
$0
$0.07
(0.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
162.66M
52-Week High
52-Week High
44.7
52-Week Low
52-Week Low
8.8
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization162.66M
icon52-Week High44.7
icon52-Week Low8.8
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Belite Bio Inc Adr do?
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Read More
News & Events about Belite Bio Inc Adr.
Globe Newswire
2 months ago
Tinlarebant (a/k/a LBS-008) is Belite Bios orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD)There are currently no approved treatments for STGD1 and Dry ...
Globe Newswire
4 months ago
1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 to be presented SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, ...
Globe Newswire
4 months ago
LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease (STGD1) and Dry AMD patientsA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoingThe Phase 3 trial ...
Globe Newswire
5 months ago
LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoingThe Phase 3, Multi-center, Randomized, Double Masked, Placebo Controlled ...
Globe Newswire
6 months ago
-LBS-008 (aka Tinlarebant) is Belite Bios orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMD-A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing-The Phase 3, Multicenter, Randomized, Double Masked, Placebo ...
Frequently Asked Questions
Frequently Asked Questions
What is Belite Bio Inc Adr share price today?
plus_minus_icon
Can Indians buy Belite Bio Inc Adr shares?
plus_minus_icon
How can I buy Belite Bio Inc Adr shares from India?
plus_minus_icon
Can Fractional shares of Belite Bio Inc Adr be purchased?
plus_minus_icon
What are the documents required to start investing in Belite Bio Inc Adr stocks?
plus_minus_icon
What is today’s traded volume of Belite Bio Inc Adr?
plus_minus_icon
What is today’s market capitalisation of Belite Bio Inc Adr?
plus_minus_icon
What is the 52-Week High and Low Range of Belite Bio Inc Adr?
plus_minus_icon
What percentage is Belite Bio Inc Adr down from its 52-Week High?
plus_minus_icon
What percentage is Belite Bio Inc Adr up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.07
(0.24%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00